Search research articles
Contact Us
Filters
Showing results (41-50 of 95) with videos related to
Page
of 10
Sort By:
VASA. Zeitschrift Fur Gefasskrankheiten
|
January 1, 1988
20 mg aspirin daily--evidence for a clinical future of this extremely low-dose in arterial disease?
H Sinzinger, K Silberbauer, J Kaliman, et al.
Lancet (London, England)
|
November 24, 1984
Effect of epoprostenol on platelet deposition on synthetic artery grafts
H Sinzinger, J O'Grady, P Fitscha, et al.
European Journal of Nuclear Medicine
|
January 1, 1986
Imaging of human atherosclerotic lesions using 123I-low-density lipoprotein
H Sinzinger, H Bergmann, J Kaliman, et al.
Progress in Clinical and Biological Research
|
January 1, 1989
Effects of omega-3 fatty acids on the prostaglandin system in healthy volunteers
A Gazsó, J Kaliman, D Horrobin, et al.
Prostaglandins
|
June 1, 1990
Successful therapy of the prostaglandin defect "Wien-Hietzing" (lack of platelet high-affinity binding sites for prostaglandin I2)
G Steurer, J Kaliman, D Gludovacz, et al.
Basic Research in Cardiology
|
November 1, 1988
Beneficial effect of PGI2 on circulating endothelial cells
H Sinzinger, F Rauscha, P Fitscha, et al.
Pacing and Clinical Electrophysiology : PACE
|
July 1, 1988
Rate dependent depression of subsidiary ventricular impulse formation--cause of Stokes-Adams attacks in a patient with rate modulated pacing
H Schmidinger, P Probst, H Weber, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids
|
November 1, 1988
Diminished platelet residence time on active human atherosclerotic lesions in-vivo--evidence for an optimal dose of aspirin?
H Sinzinger, J Kaliman, P Fitscha, et al.
Wiener Klinische Wochenschrift
|
March 29, 1985
[Defects in the prostaglandin system. II. Familial platelet-prostacyclin receptor defect (Wien-Hietzing defect)--pathogenetic significance for (early) development of atherosclerosis?]
J Kaliman, H Sinzinger, M Staudacher, et al.
Progress in Clinical and Biological Research
|
January 1, 1987
Clinical benefit and prolongation of platelet half-life induced by CG 4203, a stable PGI2-analogue
J Kaliman, P Fitscha, H Barth, et al.
Page
of 10
Search research articles
Search
Showing results (41-50 of 95) with videos related to
Sort By:
Page
of 10
VASA. Zeitschrift Fur Gefasskrankheiten
|
January 1, 1988
20 mg aspirin daily--evidence for a clinical future of this extremely low-dose in arterial disease?
H Sinzinger, K Silberbauer, J Kaliman, et al.
Lancet (London, England)
|
November 24, 1984
Effect of epoprostenol on platelet deposition on synthetic artery grafts
H Sinzinger, J O'Grady, P Fitscha, et al.
European Journal of Nuclear Medicine
|
January 1, 1986
Imaging of human atherosclerotic lesions using 123I-low-density lipoprotein
H Sinzinger, H Bergmann, J Kaliman, et al.
Progress in Clinical and Biological Research
|
January 1, 1989
Effects of omega-3 fatty acids on the prostaglandin system in healthy volunteers
A Gazsó, J Kaliman, D Horrobin, et al.
Prostaglandins
|
June 1, 1990
Successful therapy of the prostaglandin defect "Wien-Hietzing" (lack of platelet high-affinity binding sites for prostaglandin I2)
G Steurer, J Kaliman, D Gludovacz, et al.
Basic Research in Cardiology
|
November 1, 1988
Beneficial effect of PGI2 on circulating endothelial cells
H Sinzinger, F Rauscha, P Fitscha, et al.
Pacing and Clinical Electrophysiology : PACE
|
July 1, 1988
Rate dependent depression of subsidiary ventricular impulse formation--cause of Stokes-Adams attacks in a patient with rate modulated pacing
H Schmidinger, P Probst, H Weber, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids
|
November 1, 1988
Diminished platelet residence time on active human atherosclerotic lesions in-vivo--evidence for an optimal dose of aspirin?
H Sinzinger, J Kaliman, P Fitscha, et al.
Wiener Klinische Wochenschrift
|
March 29, 1985
[Defects in the prostaglandin system. II. Familial platelet-prostacyclin receptor defect (Wien-Hietzing defect)--pathogenetic significance for (early) development of atherosclerosis?]
J Kaliman, H Sinzinger, M Staudacher, et al.
Progress in Clinical and Biological Research
|
January 1, 1987
Clinical benefit and prolongation of platelet half-life induced by CG 4203, a stable PGI2-analogue
J Kaliman, P Fitscha, H Barth, et al.
Page
of 10